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Introduction. Epilepsy is one of themost common diseases of the central nervous system.The prevalence of epilepsy throughout the
world is 0.5 to 1%, and the same rate is 7.8 per 1000 in Kerman. Almost 20 to 30% of epileptic patients do not respond properly to
common medications. The present study investigated patients who did not respond to common and, even in some cases, adjuvant
therapies, with two seizures or more per week, regardless of the type of the inflicted epilepsy. Methodology. The participants of
the present double-blind study were randomly selected into three 10-member groups of uncontrolled epileptic patients (arginine,
glutamic acid, and lysine). The patients used amino acid powder dissolved in water (three times the daily need) every day for two
weeks before breakfast. The number of seizures was recorded one week prior to commencing amino acid use, as well as the first
and the second weeks subsequent to use. Results. A total of 32 patients were studied in three groups. The decline rates of seizures
were 53%, 41%, and 13%, and the P value was 0.013, 0.027, and 0.720, respectively. Conclusion. Administration of the charged amino
acids, arginine, and glutamic acid can decrease the seizures of patients suffering from uncontrolled epilepsy.
1. Introduction
Epilepsy is one of the most prevalent diseases of the central
nervous system with a prevalence of 0.5 to 1 percent of the
world population [1]. An estimated 50 million individuals
suffer from epilepsy worldwide [2, 3]. According to the
conducted studies, 7.8 per thousand individuals suffer from
epilepsy in Kerman, Iran, and are in need of anticonvulsant
medication [4]. Despite the considerable advances in the
treatment of epilepsy, especially production of new, more
tolerable anticonvulsants, 20 to 30% of the patients suffer
from uncontrolled seizures, referred to as medically resistant
[5–8].
Besides uncontrolled seizures, side effects of the admin-
istered anticonvulsants are important in treating the men-
tioned patients, which may hinder the administration of
certain anticonvulsants. Unavailability as well as unreason-
able prices of some anticonvulsant drugs may also add
to the problems. Another impediment is the psychological
complications caused by the long-term use of anticonvulsants
(besides their side effects) causing untimely discontinuation
of the drug and failed treatment [9, 10].
In addition to medical therapies, adjuvant therapies,
like avoiding facilitating factors (light, stress, and sleep
withdrawal), as well as psychiatric therapies, have received
attention by scholars [11–14].
Among the challenging issues is the diet, concerning
which different views have been reported in terms of the
efficacy and positive or negative influence of certain foods.
Ketogenic diet has long been proposed and used by the
medically resistant patients for many years. Atkins diet,
which leads to ketosis, has also received attention [15–17].
Consumption of foods containing protein chains has been
proposed as well [18].
A study on rat showed that charged amino acids are capa-
ble of elongating the seizure latency induced by intraperi-
toneal injection of pentylenetetrazole (PTZ), as well as
shortening seizure duration [19].
Charged amino acids are of two types, acidic or basic,
depending on their Ph in the physiological environment.Glu-
tamic and aspartic amino acids are acidic, while arginine and
lysine are basic. Besides being a stimulator neurotransmitter,
glutamic acid, as an acidic charged amino acid, plays a great
role in the brain metabolism [20, 21], present in different
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brain parts and synapses, which functions via ionotropic
or metabotropic receptors [22–25]. Another property of the
glutamate brain metabolism is its close association with the
citric acid cycle and energy metabolism [24, 26].
Arginine is a basic amino acid, and according to exten-
sive studies of 1950 through to 1970, it is considered as a
nonessential amino acid for the health of adults [27] and an
essential amino acid for the growth of human beings and
animals [28, 29]. However, upon the inflection of diseases, as
well as physical traumas, it turns into an essential amino acid
[30]. The sources of free arginine within the body are dietary
protein, endogenous synthesis, and turnover of body proteins
[31–34].
The importance of lysine is due to its involvement in the
collagen construction. It is also among the most important
components of the conjunctival tissue, essential for growth.
Lysine is important for carnitine synthesis. The daily amount
of lysine intake is 40–180mg per kilogram of body weight;
however, there have been reports of up to 300–400mg intake
[35].
The present study investigated the effects of charged
amino acids on the seizures of uncontrolled epilepsy patients.
2. Methodology
As an interventional study, the present research investigated
epilepsy patients who referred to the Neurology Clinic of
Shafa Medical Center a subsidiary of Kerman University of
Medical Sciences, Kerman, Iran, as well as private clinics,
regardless of the type of the inflicted epilepsy, and who,
despite using multiple anticonvulsant regimens, still expe-
rienced seizures, though drug side effects were observable.
To allow for a better assessment, patients with at least two
seizures in a week entered the study.
Prior to inclusion, the entire necessary examinations
including self-report, follow-ups, EEG, and imaging were
conducted by a neurologist to ensure the presence of epilepsy.
It was ensured that the patients who entered the study, or their
companions, were made aware of the fact that the mentioned
substances have never been administered for such cases and
also the possibility that it was probably the first time they,
or their patients, were going to have an examination. Sub-
sequently the participants declared their informed consent
and were included. The patients were allowed to leave the
program whenever they demanded.
It should be mentioned that use of these substances is
embedded in humans daily diet, and furthermore there have
been no reports concerning associated complications, and
they do not seem to induce certain disorders, as the toxic
dosage of the utilized substances is 50–500 times the daily
required amount [36].
Patients who suffered fromdiseases other than epilepsy (a
primary brain disease) were refused to enter the study. Preg-
nant women and breastfeeding mothers [37–39], psychotic
patients [38, 39], and patients suffering from infections,
particularly viral infections, were excluded.
Duration of the treatment was two weeks. The patients
or their companions were asked to record the number of
the seizures. The number of the seizures was recorded one
week prior to amino acid use. The patients used amino acid
powder dissolved in water, three times the daily need, and
every day before breakfast. The number of seizures was once
again recorded one week later. In case any complications
(nausea, vomit) were reported, the patient was excluded from
the study.
Charged amino acids are of 4 types, three of which were
investigated in the present study. Aspartic acid was left out as
it could not be procured and since it can replace glutamic acid
in the body.
The amount of administered glutamic acid was a daily
dosage of 10 grams for adults and 2 grams for children under
2 years of age.The administered lysine was a daily dosage of 6
grams for adults and 90mg for children per kilogram of body
weight. And arginine was administered at a daily dosage of
15 grams for adults and 240mg for children per kilogram of
body weight [40].
The patients were divided into three groups of 10 (with
regard to the available patients) and each group was put
on one of the foregone amino acids. The participants were
randomly selected and appointed to a group. Allocating an
amino acid to one of the three groupswas double blinded; that
is, neither the patient nor the attending physicians were aware
of the type of the amino acid administered. The pertinent
amino acids were already placed in packets of 14, handed to
the patient bearing only a number.The packaging was carried
out prior to prescription; as a result, the treating physicians
were unaware of the contents.
The collected data went through statistical analysis. The
results were compared to the recorded data prior to com-
mencement of the study and the results from the three
groups were compared. The recorded findings from the two
previous stages as well as one and two weeks subsequent to
administration as well as the number of seizures in the three
groups were compared.
3. Results
Anumber of 45 patients were studied, of whom 13 individuals
were excluded due to experiencing nausea and vomit and
refusing cooperation resulting from tastelessness or unde-
sirable taste of arginine, which left us with the remaining
cooperative 32 patients.
Table 1 shows the number of patients in each group
along with the average weekly seizures, one week prior to
amino acid administration, and the first and second weeks
after treatment commencement, respectively, as well as the
proportion of the seizures of the second week compared to
those of the week leading to treatment.
Sex distribution of the patients, according to the used
amino acid, is presented in Table 2. There were no significant
differences between the three study groups (𝑃 = 0.28).
Age distribution of the patients, according to the used
amino acid, is presented in Table 3. There were no significant
differences between the three study groups (𝑃 = 0.7).
Table 4 portrays the frequency of the different types of
uncontrolled epilepsies in terms of the administered amino
acid.
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Table 1: The rate of seizure attacks (one week before starting amino acid, first week after starting, second week, and ratio of second week to
before starting).
Amino acid Number Before starting First week Second week Ratio before/second 𝑡-test 𝑃 value
Arginine 10 23.6 ± 16.2 21.6 ± 14.2 11.2 ± 11.5 0.47 3.139 0.013
Glutamic acid 11 31.3 ± 36.2 31.4 ± 36.5 18.54 ± 21.1 0.59 2.646 0.027
Lysine 11 11.4 ± 9.9 12.2 ± 13.7 10 ± 15.5 0.87 0.368 0.720





Male 8 5 7 20
Female 2 6 4 12
Total 10 11 11 32
𝑃 = 0.28.
Table 3: Mean age of patients.
Amino acid/mean age Number Mean of ages
Arginine 10 16.2 ± 10.4
Glutamic acid 11 12.27 ± 12.8
Lysine 11 13.27 ± 10.7
𝑃 = 0.7.
4. Discussion
Amino acids are vital for brain activity, the general deficiency
of which may cause apathy, impaired concentration, loss of
motivation, insomnia, mood disorders, anxiety, depression,
self-harm, and aggression.They are essential in the construc-
tion of necessary and important proteins for the production
of neurotransmitters required for the nervous system. Poor
diets may lead to amino acid shortage and give rise to a
genetic potentiality for amino acid deficiency [41].
Use of amino acids is greatly influential on paroxysmal
disorders and the psychopathologic components of epilepsy.
As for infants, administration of amino acids contributes
to the mental and verbal development. The positive effects
of amino acids in children will take 7–10 days to function,
which may remain for a long time despite discontinuation.
Amino acids may, furthermore, be effective in changing
generalized epilepsy into focal epilepsy, as well as decreasing
the frequency of epileptic seizures [42].
Acid glutamic managed to reduce the seizure frequency
(𝑃 = 0.027) in uncontrolled epilepsy patients by more
than 40% (Table 1). Studies conducted in the past few
decades are evidence for the role of glutamic acid in epilepsy
[43], which depends on the glutamate receptors, some of
which have intensifying effects (type 1) and some other
anticonvulsant effects (types 2 and 3) [44]. Effects of these
receptors aremainly corrective, rather than directly stimulant
or prohibitory [45]. It is assumed that oral amino acids may
reinforce the roles of receptors in the natural course and,
accordingly, improve controlling epileptic seizures.
Arginine could also reduce the seizure frequency (𝑃 =
0.013) in uncontrolled epilepsy patients by 53% (Table 1).
L-arginine is an amino acid commonly sold in supplement
form and obtained naturally in the diet. L-arginine-rich foods
include plant and animal proteins, such as dairy. Arginine is
a nonessential amino acid, the internal production of which
is, however, insufficient and needs to be compensated for
orally [30, 46, 47]. Arginine regulation is a subject of the
extent of oral use and its internal production; hence, arginine
needs to be viewed as a semiessential amino acid [31]. The
ultimate metabolism of arginine leads to three substances
of nitrous oxide, agmatine, and glutamic acid. Nitric oxide
(NO) is a highly reactive and unstable substance with a very
short half-life, which is a potent vasodilator acting via the
intracellular second-messenger cGMP. In healthy humans, l-
arginine induces peripheral vasodilation and inhibits platelet
aggregation due to an increased NO production [48], but
acute L-arginine supplementation does not increase plasma
concentration of NOx in healthy individuals with normal
plasma concentrations of ADMA [49].
Agmatine, a product of arginine decarboxylation, influ-
ences multiple physiologic and metabolic functions. The
findings suggest that AGM elevated the synthesis and levels
of cAMP, thereby mimicking the effects of caloric restriction
with respect to metabolic reprogramming [50]. The effects
of injected agmatine in animals include anticonvulsant-,
antineurotoxic-, and antidepressant-like actions [51]. Agma-
tine has neuroprotective effects [52].
The effectiveness of arginine in reducing seizure fre-
quency may be due to the increase of glutamate level, rather
than the direct intervention of arginine itself, as the partic-
ipants of the present study, in the two groups of glutamic
acid and arginine, show no significant difference in terms of
age (Table 3) and sex distribution (Table 2). Two products of
arginine: glutamic acid and agmatine may be involved for
anticonvulsant effects of arginine.
Concerning lysine, no significant decrease (𝑃 = 0.720)
was observed in reducing seizure frequency in uncontrolled
epilepsy patients (13%). A study has reported that the
intraperitoneal injection of lysine reduces the severity of
PTZ-induced seizures [53, 54]. As for the present study,mode
of lysine administration was oral. In another study on rats
with oral lysine administered, similar results were reported
[19].
In this study we could not evaluate the effect of charged
amino acid on different types of epilepsy due to our limited
cases (Table 4).
5. Conclusion
Administration of arginine and glutamic acid can be effective
in reducing the seizure frequency of uncontrolled epilepsy
patients, without triggering considerable complications.
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Table 4: The type of seizures in this study.
Amino/type of seizure Tonic-clonic F-G Atypical Lennox-Gastaut CPS Myoclonic Total
Arginine 3 3 1 1 2 0 10
Glutamic acid 0 3 2 2 1 3 11
Lysine 2 2 1 2 2 2 11
Total 5 8 4 5 5 5 32
F-G: secondary generalized, CPS: complex partial seizure, and LGS: Lennox-Gastaut syndrome.
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